Rafal Chojak

Dr. Rafal Chojak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RCRafal Chojak
Rafal Chojak
MKMarta Koźba-Gosztyła
Marta Koźba-Gosztyła
KSKatarzyna Słychan
Katarzyna Słychan
DGDaniel Gajos
Daniel Gajos
MKMarek Kotas
Marek Kotas
BCBogdan Czapiga
Bogdan Czapiga
Butterfly glioblastoma (bGBM) is a rare brain tumor that invades both hemispheres by crossing the corpus callosum. bGBM is associated with a dismal prognosis with a median survival time of a few months. Surgical resection is a rare treatment option due to the unfavorable location and assumed poor risk-to-benefit ratio. Therefore, a biopsy-alone approach is considered the main treatment option. This meta-analysis aimed to systematically evaluate whether resection of bGBM is associated with improved overall survival compared with biopsy alone. We searched three databases to find studies that compare resection with biopsy in 6-, 12- and 18-months overall survival in patients with bGBM. We calculated the pooled relative risk (RR) of mortality using a random-effects model. Five studies with 194 patients were included in the meta-analysis. Mortality was decreased for resection compared with biopsy at 6-months (RR 0.63 [95% CI 0.44–0.91]). No significant differences in overall survival were found at 12 (RR 0.76 [95% CI 0.50–1.14]) and 18-months (RR 0.84 [95% CI 0.56–1.26]). Surgical resection of bGBM is associated with an improved 6-months overall survival compared with biopsy alone. We have not found strong evidence supporting the superiority of resection over biopsy alone in overall survival at 12 and 18-months.

8 June 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
RCRafal Chojak
Rafal Chojak
MKMarta Koźba-Gosztyła
Marta Koźba-Gosztyła
MGMagdalena Gaik
Magdalena Gaik
MMMarta Madej
Marta Madej
AMAleksandra Majerska
Aleksandra Majerska
BCBogdan Czapiga
Bogdan Czapiga
Meningitis is a potential complication of elective intracranial surgery (EIS). The prevalence of meningitis after EIS varies greatly in the literature. The objective of this study was to estimate the overall pooled prevalence of meningitis following EIS. Four databases (PubMed, Scopus, Web of Science, and Embase) were searched to identify relevant studies. Meta-analyses of proportions were used to combine data. Cochran's Q and I2 statistics were used to assess and quantify heterogeneity. Additionally, several subgroup analyses were conducted to investigate the source of heterogeneity and examine differences in the prevalence based on variables such as geographical regions, income level, and meningitis type. The meta-analysis included 83 studies (30 959 patients) from 26 countries. The overall pooled prevalence of meningitis after EIS was 1.6% (95% CI 1.1–2.1), with high heterogeneity present (I2 = 88%). The pooled prevalence in low- to middle-income countries and high-income countries was 2.7% (95% CI 1.6–4.1) and 1.2% (95% CI 0.8–1.7), respectively. Studies that reported only aseptic meningitis had a pooled prevalence of 3.2% (95% CI 1.3–5.8). The pooled prevalence was 2.8% (95% CI 1.5–4.5) in studies that reported only bacterial meningitis. Similar prevalence rates of meningitis were observed in the subgroups of tumor resection, microvascular decompression, and aneurysm clipping. Meningitis is a rare but not exceptional complication following EIS, with an estimated prevalence of 1.6%.

30 November 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
RCRafal Chojak
Rafal Chojak
MKMarta Koźba-Gosztyła
Marta Koźba-Gosztyła
KPKarolina Polańska
Karolina Polańska
MRMarta Rojek
Marta Rojek
ACAleksandra Chojko
Aleksandra Chojko
BCBogdan Czapiga
Bogdan Czapiga
Purpose: Despite the improvement in treatment and prognosis of primary central nervous system lymphoma (PCNSL) over the last decades, the 5-year survival rate is approximately 30%; thus, new therapeutic approaches are needed to improve patient survival. The study’s aim was to evaluate the role of surgical resection of PCNSL. Methods: Primary outcomes were the overall survival (OS) and progression-free survival (PFS) of patients with PCNSL who underwent surgical resection versus biopsy alone. The meta-analysis was conducted to calculate pooled hazard ratios (HRs) under a random-effects model for the time-to-event variables. The odds ratios (ORs) were calculated for binary, secondary outcome parameters. Results: Seven studies (n = 1046) were included. We found that surgical resection was associated with significantly better OS (HR 0.63 [95% CI 0.51–0.77]) when compared with biopsy. PFS was also significantly improved (HR 0.64 [95% CI 0.49–0.85]) in patients who underwent resection compared with those who underwent biopsy. The heterogeneity for OS and PFS was low (I2 = 7% and 24%, respectively). We also found that patients who underwent biopsy more often had multiple (OR 0.38 [95% CI 0.19–0.79]) or deep-seated (OR 0.20 [95% CI 0.12–0.34]) lesions compared with those who underwent surgical resection. There were no significant differences in chemotherapy or radiotherapy use or the occurrence of postoperative complications between the two groups. Conclusion: In selected patients, surgical resection of PCNSL is associated with significantly better overall survival and progression-free survival compared with biopsy alone.

24 September 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
RCRafal Chojak
Rafal Chojak
MKMarta Koźba-Gosztyła
Marta Koźba-Gosztyła
MPMateusz Pawłowski
Mateusz Pawłowski
BCBogdan Czapiga
Bogdan Czapiga
Background: Most traumatic brain injuries (TBIs) are mild (GCS score of 13–15). Patients with mild TBI (mTBI) are generally in good condition. In some cases, a neurological deterioration (manifested by a drop of ≥1 point in GCS score) can occur and neurosurgical intervention (NI) may be needed. Because of that, these patients are frequently admitted to a hospital for observation. The aim of our study was to determine the number of patients with mTBI that deteriorate or need NI. We also considered an economic aspect of hospital admissions of these patients.Methods: The study group consisted of 186 adult patients admitted to the neurosurgical department due to mTBI. Patients were divided into three groups according to an initial GCS score. The occurrence of deterioration, need for NI, length of stay (LOS), cost of stay and occurrence of death were analyzed.Results: The deterioration was observed in 7 (3.76%) out of all cases. In 3 (1.61%) of them, the NI was needed. The average LOS was 7.96 days and it was closely linked with an initial GCS score (p < 0.001). The total cost of stay of all patients included in this study was about 1,188,668 PLN (306,357 USD).Conclusion: The deterioration occurred in a small number of patients with mTBI, the need for NI was even less common. Hospitalization of these patients is expensive. Further studies with prognostic model helping decide on admission/discharge are necessary.

26 March 2025 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
KSKatarzyna Słychan
Katarzyna Słychan
MPMarcin Piersiak
Marcin Piersiak
JRJakub Rubin
Jakub Rubin
AKAleksandra Kozioł
Aleksandra Kozioł
MTMichał Tyliszczak
Michał Tyliszczak
RCRafal Chojak
Rafal Chojak

30 July 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
RCRafal Chojak
Rafal Chojak
NDNoah B. Drewes
Noah B. Drewes
KSKatarzyna Slychan
Katarzyna Slychan
RLRimas V. Lukas
Rimas V. Lukas
Purpose: Spatial patterns of glioblastoma (GBM) progression inform focal salvage eligibility, but interpretation across studies is limited by heterogeneous spatial definitions, high between-study heterogeneity, and incomplete reporting of non-enhancing/FLAIR-dominant progression. We synthesized reported progression-location involvement after upfront radiotherapy/temozolomide (RT/TMZ) and salvage therapy. Methods: We systematically searched PubMed and Scopus from January 1, 2000, to February 1, 2026, and performed arm-level random-effects meta-analysis of logit-transformed proportions. Enhancing progression was harmonized as non-mutually exclusive local/in-field, marginal/field-edge, and distant/out-of-field involvement among evaluable cases, using each study’s spatial framework. The supplementary broad escape-pattern construct was defined as reported progression beyond purely local/in-field enhancing failure. Results: We included 107 studies (122 arms; 10,529 patients). At first progression after upfront RT/TMZ ± TTF, reported local/in-field enhancing involvement among evaluable cases was 79.2% (95% CI 75.7–82.3; k = 94; n = 6,989; I²=84.8%), and distant/out-of-field involvement was 16.9% (95% CI 14.3–19.9; k = 89; n = 6,493; I²=85.2%). After salvage therapy, local/in-field involvement remained the majority pattern reported among evaluable cases (59.8%, 95% CI 52.8–66.4; k = 27; n = 1,572; I²=80.5%), with distant/out-of-field involvement of 17.5% (95% CI 12.9–23.3; k = 21; n = 1,307; I²=75.5%) and a supplementary broad escape-pattern estimate of 38.6% (95% CI 31.9–45.9; k = 27; n = 1,572; I²=80.1%). Non-enhancing/FLAIR-dominant progression was sparsely and likely selectively reported; only six recurrent/salvage arms contributed data, yielding an exploratory pooled estimate of 27.8% (95% CI 12.8–50.3; n = 216; I²=75.7%). Conclusion: Published GBM cohorts show predominantly local/in-field enhancing progression after upfront therapy (~ 80%) and persistent majority local/in-field involvement after salvage therapy (~ 60%). Standardized reporting of enhancing, non-enhancing/FLAIR-dominant, disseminated, posterior fossa, and brainstem progression is needed.